GRK1 and viral infectious disease: To investigate whether delayed G-rk1 administration would affect its protection for IAV-infected mice, which might mimic early clinical treatment, 25 mg/kg/d of G-rk1 was given to mice by intranasal inoculation at 24 or 4 h prior to or 24, 48, or 72 h post PR8 virus infection, followed by G-rk1 treatment for 6 consecutive days.